Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…
HOME > COLUMN
COLUMN
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
- “Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
- Our Habits Determine Our Success
August 8, 2012
- Marketing Is More than a Pen and a Tissue Box
July 9, 2012
- Science without Works Is Dead
June 4, 2012
- Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
- The Eight Characteristics of a Great Leader
April 2, 2012
- Maurer’s Healthcare Insight (143)
March 26, 2012
- Maurer’s Healthcare Insight (142)
February 27, 2012
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
- Maurer’s Healthcare Insight (139)
December 12, 2011
- Maurer’s Healthcare Insight (138)
November 21, 2011
- Maurer’s Healthcare Insight（137）
October 17, 2011
- Maurer’s Healthcare Insight (136)
September 12, 2011
- Maurer's Healthcare Insight (135)
August 15, 2011
- Maurer's Healthcare Insight (134)
August 1, 2011
ページ
With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…